Dublin, Dec. 19, 2017 -- The "Global Infertility Treatment Market Analysis By Procedure (ART, Artificial Insemination, Fertility Surgery, Fertility Drugs, Others), Establishment (Fertility Clinics, Hospitals, Research Banks), By Region, By Country (2012-2022)" report has been added to Research and Markets' offering.
The global market is projected to display a robust growth represented by a CAGR of 8.25% during 2017-2022, chiefly driven by favourable government reforms as well as introduction of new techniques of IVF.
Over the recent years, the global infertility treatment has been growing rapidly on account of rising awareness of infertility treatment through government awareness campaign, rising demand of IVF treatment worldwide and surge in medical tourism.
Among the regions, Europe is predicted to advance at the highest rate, mainly driven by high acceptance of new techniques, rising medical tourism in UK and favourable insurance policies.
Scope of the Report
Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
- Infertility Treatment Market
- Infertility Treatment Procedure - ART or Assisted Reproductive Technique, Artificial Insemination, Fertility Surgery, Fertility Drugs, Other Procedures
- By ART Type - IVF, ICSI, Other Procedure
- Analysis By Patient Type - Male and Female
Key Topics Covered:
1. Research Methodology
2. Executive Summary
3. Strategic Recommendations
4. Infertility Treatment Market Outlook
5. Global Infertility Treatment Market: Growth and Forecast
6. Global Infertility Treatment Market - Analysis By Procedure
7. Global Infertility Treatment Market- By ART Procedure
8. Global Infertility Treatment Market- By Patient Type
9. Global Infertility Treatment Market - By Establishment
10. Global Infertility Treatment Market - Regional Analysis
11. Global Infertility Treatment Market Dynamics
12. Market Trends
13. Porter's Five Force Analysis
14. SWOT Analysis
15. Policy and Regulations
16. Company Profiles
- CCRM
- Ferring Pharmaceutical
- Merck & Co
- Monash IVF Group
- The Cooper Company
- Thermo Fisher
- United Healthcare Group
For more information about this report visit https://www.researchandmarkets.com/research/twwbtl/global?w=12
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health, Sexual and Reproductive Health Drugs


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
Amazon Explores AI Content Marketplace With Media Publishers
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 



